PYA Waltman Capital LLC Raises Holdings in Johnson & Johnson (NYSE:JNJ)

PYA Waltman Capital LLC increased its holdings in Johnson & Johnson (NYSE:JNJ) by 3.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 39,927 shares of the company’s stock after acquiring an additional 1,217 shares during the quarter. Johnson & Johnson makes up about 2.1% of PYA Waltman Capital LLC’s investment portfolio, making the stock its 13th largest position. PYA Waltman Capital LLC’s holdings in Johnson & Johnson were worth $6,471,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Occidental Asset Management LLC raised its stake in Johnson & Johnson by 21.6% in the second quarter. Occidental Asset Management LLC now owns 3,416 shares of the company’s stock valued at $499,000 after buying an additional 607 shares during the last quarter. Bangor Savings Bank increased its stake in Johnson & Johnson by 3.0% during the 2nd quarter. Bangor Savings Bank now owns 26,933 shares of the company’s stock valued at $3,936,000 after purchasing an additional 776 shares in the last quarter. Voisard Asset Management Group Inc. raised its holdings in shares of Johnson & Johnson by 93.2% in the second quarter. Voisard Asset Management Group Inc. now owns 1,244 shares of the company’s stock worth $182,000 after buying an additional 600 shares during the last quarter. JFS Wealth Advisors LLC lifted its stake in shares of Johnson & Johnson by 29.6% during the second quarter. JFS Wealth Advisors LLC now owns 20,461 shares of the company’s stock worth $2,991,000 after buying an additional 4,671 shares during the period. Finally, Brendel Financial Advisors LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at $857,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $149.31 on Monday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The stock’s fifty day moving average is $158.09 and its two-hundred day moving average is $156.40. The company has a market capitalization of $359.48 billion, a P/E ratio of 21.61, a P/E/G ratio of 2.65 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.66 earnings per share. Equities analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.32%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Guggenheim lifted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Royal Bank of Canada increased their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, Citigroup raised their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $175.67.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.